ALK Inhibition With Alectinib for Refractory Metastatic Renal Cell Carcinoma With ALK Rearrangement: A Rare Case Report and Literature Review.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 38885453.
- Also identified by DOI 10.1200/PO.24.00154.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
ALK-rearranged RCC refractory to several lines of treatment has a durable response when treated with alectinib.
Medical subject headings
- Anaplastic Lymphoma Kinase
- Carbazoles
- Carcinoma, Renal Cell
- Gene Rearrangement
- Kidney Neoplasms
- Piperidines